NCT02783625 2025-06-03Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasMemorial Sloan Kettering Cancer CenterPhase 1 Active not recruiting114 enrolled